VSAR - Versartis, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
1.1900
-0.0200 (-1.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.2100
Open1.2200
Bid0.00 x 4000
Ask0.00 x 3200
Day's Range1.1802 - 1.3000
52 Week Range1.1802 - 1.3000
Volume349,963
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?
    Simply Wall St.5 months ago

    Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?

    Every investor in Versartis Inc (NASDAQ:VSAR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...

  • Associated Press6 months ago

    Versartis: 2Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 27 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $1.78. A year ago, they were trading at $17.95. _____ ...

  • Versartis Stock and Its Consistent Rise in the Week Ended June 8
    Market Realist8 months ago

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.

  • ACCESSWIRE8 months ago

    Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Sarepta Therapeutics, Inc. (NASDAQ: SRPT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SRPT as the Company's latest news hit the wire. On June 01, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion against approval for EXONDYS® (eteplirsen) for treatment of patients with Duchenne muscular dystrophy (DMD).

  • ACCESSWIRE8 months ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • GuruFocus.com11 months ago

    Versartis Inc (VSAR) Files 10-K for the Fiscal Year Ended on December 31, 2017

    Versartis Inc (NASDAQ:VSAR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.